PF-Atlas › Clinical Trials › NCT01953367
Bioequivalence and Safety of Vantobra and TOBI in Healthy Subjects
Vantobra · Phase 1
Registry ID
NCT01953367
Phase
Phase 1
Status
Completed
Drug / intervention
Vantobra (tobramycin)
Sponsor
Pari Pharma GmbH
Start
2013-09
About this trial
Vantobra is evaluated in NCT01953367, a Phase 1 idiopathic pulmonary fibrosis study sponsored by Pari Pharma GmbH. Current status: Completed.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT01953367 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.